Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.53

+4.5%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Michael Young who wrote (3534)	4/22/2001 10:54:48 PM
From: Biomaven	of 52153

<<ITMN>> Mike, A trial entry criterion is biopsy-proven IPF. There has now developed a consensus on IPF diagnosis from histopathology (usual interstitial pneumonia - UIP), so I feel they have a clearly defined disease entity. If you are interested in IPF and Intermune, the following monograph is very informative: Title: "New Approaches to Managing Idiopathic Pulmonary Fibrosis:" Summary: “New Approaches to Managing Idiopathic Pulmonary Fibrosis” is an educational monograph that was published by the American Thoracic Society (ATS) in September 2000. The monograph was developed from the proceedings of an ATS advisory panel held in April 2000 and reviews advances in the diagnosis and treatment of idiopathic pulmonary fibrosis (IPF), a life-threatening pulmonary disease. You can get a PDF of it at: intermune.com In particular, note the paper by the Austrian doctors on interferon-gamma in IPF and the following paper, which is an independent re-analysis of the Austrian's NEJM article. Personally, I put the odds of approval for IPF at well over 50%. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next